scholarly journals Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells

2020 ◽  
Vol 122 (7) ◽  
pp. 1005-1013 ◽  
Author(s):  
Sanjay Varikuti ◽  
Bhawana Singh ◽  
Greta Volpedo ◽  
Dinesh K. Ahirwar ◽  
Bijay K. Jha ◽  
...  
2012 ◽  
Vol 1 (9) ◽  
pp. 1484-1494 ◽  
Author(s):  
Sabrina Danilin ◽  
Alyssa R. Merkel ◽  
Joshua R. Johnson ◽  
Rachelle W. Johnson ◽  
James R. Edwards ◽  
...  

2012 ◽  
Vol 72 (23) ◽  
pp. 6130-6141 ◽  
Author(s):  
Julien Faget ◽  
Nathalie Bendriss-Vermare ◽  
Michael Gobert ◽  
Isabelle Durand ◽  
Daniel Olive ◽  
...  

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Thomas Welte ◽  
Xiang H.-F. Zhang

Metastatic disease accounts for more than 90% of deaths from breast cancer. Yet the factors that trigger metastasis, often years after primary tumor removal, are not understood well. Recently the proinflammatory cytokine interleukin- (IL-) 17 family has been associated with poor prognosis in breast cancer. Here we review current literature on the pathogenic mechanisms driven by IL-17 during breast cancer progression and connect these findings to metastasis. These include (1) direct effects of IL-17 on tumor cells promoting tumor cell survival and invasiveness, (2) regulation of tumor angiogenesis, and (3) interaction with myeloid derived suppressor cells (MDSCs) to inhibit antitumor immune response and collaborate at the distant metastatic site. Furthermore, IL-17 might also be a culprit in bone destruction caused by late stage bone metastasis. Interestingly, in addition to these potential prometastasis functions, there is also evidence for an opposite, antitumor role of IL-17 during cancer therapies. We hypothesize that these contradictory roles may be due to chronic, imbalanced versus acute transient nature of the immune reactions, as well as differences in the cells that interact with IL-17+cells under different circumstances.


2021 ◽  
Vol 11 ◽  
Author(s):  
Ji-Eun Irene Yum ◽  
Young-Kwon Hong

VISTA is an up-and-coming immune checkpoint molecule that can become the target of new cancer immunotherapy treatments. Immune cells in the tumor microenvironment can largely influence the progression of cancer through inhibitory and stimulatory pathways. Indeed, VISTA is expressed on many immune cells, including T cells, myeloid-derived suppressor cells, tumor-associated macrophages, and dendritic cells. VISTA has predominantly been shown to act in an immune-suppressing manner that enables cancer progression. This review will delve into results from preclinical murine studies of anti-VISTA monoclonal antibody treatments, bring together recent studies that detect VISTA expression on immune cells from patient tumors of various cancers, and discuss ongoing clinical trials involving VISTA.


2014 ◽  
Author(s):  
Mattia Capulli ◽  
Adriano Angelucci ◽  
Anna Teti ◽  
Patrizia Sanita ◽  
Luca Ventura ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document